Business
Aytu BioPharma to Present at Upcoming September 2025 Conferences
DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality ...
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences:","length":372,"tagName":"p"},{"type":"text","content":"MicroCap Rodeo Fall Conference","length":30,"tagName":"p"},{"type":"text","content":"Date: Thursday, September 25, 2025Location: New York CityPresentation Time: 2:00 p.m. Eastern timeWebcast: https://www.webcaster5.com/Webcast/Page/3142/53024","length":160,"tagName":"p"},{"type":"text","content":"Lytham Partners Fall 2025 Investor Conference","length":45,"tagName":"p"},{"type":"text","content":"Date: Tuesday, September 30, 2025Location: VirtualPresentation Time: 2:45 p.m. Eastern timeWebcast: https://app.webinar.net/K8vDlaelmAd","length":138,"tagName":"p"},{"type":"text","content":"Management will be participating in one-on-one meetings throughout both events. To arrange a meeting with management, please contact Robert Blum of Lytham Partners at [email protected].","length":191,"tagName":"p"},{"type":"text","content":"About Aytu BioPharma","length":20,"tagName":"p"},{"type":"text","content":"Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.","length":873,"tagName":"p"},{"type":"text","content":"Contacts for Investors","length":22,"tagName":"p"},{"type":"text","content":"Ryan Selhorn, Chief Finan...